Acalabrutinib is a type of medicine called a Bruton tyrosine kinase (BTK) inhibitor. BTK is a protein that plays a key role in the survival and growth of certain types of blood cancer cells, especially B-cell malignancies. By blocking BTK, acalabrutinib disrupts signals that cancer cells need to grow and divide. This helps to slow down or stop the progression of blood cancers such as mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL).

Acalabrutinib and its active metabolite (ACP-5862) form a bond with the BTK protein, leading to its inactivation. This action prevents B-cell cancer cells from proliferating, moving, and adhering to other cells, which can help control the disease. In clinical studies, acalabrutinib has shown to maintain high levels of BTK inhibition throughout the dosing interval, contributing to its effectiveness in treating blood cancers.

acalabrutinib

Common brand names

Approved use in